Common Contracts

Pliant Therapeutics, Inc. 8,333,334 Shares Common Stock (par value $0.0001 per share) Underwriting Agreement

Pliant Therapeutics, Inc. • January 25th, 2023 • Pharmaceutical preparations • New York

• Company
  Pliant Therapeutics, Inc.
• Filed
  January 25th, 2023
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, collectively with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the

Pliant Therapeutics, Inc. 10,810,811 Shares Common Stock ($0.0001 par value) Underwriting Agreement

Pliant Therapeutics, Inc. • July 14th, 2022 • Pharmaceutical preparations • New York

• Company
  Pliant Therapeutics, Inc.
• Filed
  July 14th, 2022
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”) of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plu

OWL ROCK CAPITAL CORPORATION [●] SHARES OF COMMON STOCK Underwriting Agreement

Owl Rock Capital Corp • June 25th, 2019 • New York

• Company
  Owl Rock Capital Corp
• Filed
  June 25th, 2019
• Jurisdiction
  New York

Owl Rock Capital Corporation, a Maryland corporation (the “Company”), proposes subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule 1 hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 11 hereof), for whom you are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the